Figures
- FIGURE 1
Delphi consensus on whether patients should be treated based on the presence of pulmonary symptoms, pulmonary function testing and imaging. Bold indicates consensus. HRCT: high-resolution computed tomography; PFT: pulmonary function test; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide.
- FIGURE 2
Delphi consensus on the role of extrapulmonary disease in treatment decisions. Bold indicates consensus.
- FIGURE 3
Delphi consensus on clinical situations in which immediate therapy is warranted. PFT: pulmonary function test; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s.
- FIGURE 4
Delphi consensus on clinical situations in which second-line therapies (usually non-biologic cytotoxic agents) and third-line therapies (usually biologic agents) should be considered. Bold indicates consensus.
Tables
- TABLE 1
Phenotype scales reported in sarcoidosis
First author [ref.] Phenotype Description of developing phenotype Patients n Validation Single versus multi-centre Established association to genotype Comments Scadding [5] Pulmonary Chest radiograph stage 136 No Single No Did not use computed tomography Neville [7] Acute versus chronic Rate of resolution 818 No Single No Did not account for more than one factor in patient Grunewald [3, 8] Löfgren versus non-Löfgren Clinical outcome of Löfgren patients 754 Yes Single Yes Series of studies, may not apply to other racial groups Wasfi [9] Severe versus non-severe Backward regression based on clinical parameters 104 Two different groups of clinicians assessed same patients Single No Based on expert opinion, no follow-up analysis Prasse [10] Acute versus chronic and duration of treatment Evaluated patients seen within 1 year of presentation 225 No Single No More useful for acute disease Baughman[11] Acute versus chronic including therapy Developed criteria for long-term outcome 500 No Multi-centre No Retrospective look based on expert opinion Rodrigues[12] Acute, relapse, fibrosis Factor analysis 137 No Multi-centre No Phenotypes were not distinct Walsh [13] Severe versus non-severe Regression analysis of multiple factors 251 Yes (additional 252) Single No Only focused on advanced pulmonary disease Moller [14] Various groups of patients Expert opinion of grouping of patients Not given No Multi-centre Yes Established criteria to be studied Schupp [15] Organ clustering Multi-factor analysis based on gene expression 2163 No Multi-centre Yes Used genetic profile to identify associated organ manifestations
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary_appendix ERR-0145-2019_Supplementary_appendix
